Use of beta-catenin antagonist and immunomodulator

WO2024216238A3PCT designated stage expired Publication Date: 2024-11-21SAPIENCE THERAPEUTICS INC
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
PCT/US2024/024530
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-04-13
Filing Date
2024-04-13
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

The Wnt/β-catenin signaling pathway is frequently deregulated in various cancers, leading to carcinogenesis and poor prognosis, and existing therapies struggle to effectively target the interaction between β-catenin and its co-activator BCL9, which drives oncogenic Wnt/β-catenin transcription.

Method used

A combination therapy approach using a peptide antagonist of β-catenin, such as ST316, which disrupts the interaction with BCL9, administered alongside an immunomodulator like a PD-1 inhibitor, to inhibit tumor growth and reprogram the tumor microenvironment by promoting an immune-promoting phenotype in macrophages.

Benefits of technology

This combination therapy demonstrates significant inhibition of tumor growth and volume reduction in solid tumors, including triple-negative breast cancer, by enhancing anti-tumor immunity and modulating tumor cell surface markers, achieving improved anti-tumor activity compared to either treatment alone.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2024024530_21112024_PF_FP_ABST
    Figure US2024024530_21112024_PF_FP_ABST
Patent Text Reader

Abstract

Provided are methods of administering a peptide antagonist of β-catenin in combination with an immunomodulating agent.
Need to check novelty before this filing date? Find Prior Art

Description

Sapience.022. WO1PATENTUSE OF BETA-CATENIN ANTAGONIST AND IMMUNOMODULATORBACKGROUND

[0001] The Wnt / p-catenin pathway is a validated target for cancer therapies. Constitutive activation of the Wnt / p-catenin signaling pathway is implicated in carcinogenesis, tumor progression, and poor prognosis of many malignancies (Shang 2017). The transcription factor p-catenin is a key player in many cellular processes, including stem cell renewal, cellular homeostasis and inflammation. Deregulation of P- catenin occurs frequently in several cancer types by mutation or overexpression of the P- catenin gene, or by mutation of negative regulators such as Adenomatous Polyposis Coli (APC).

[0002] The complex formed by the interaction between P-catenin and its co-activator, B-cell CLL / lymphoma 9 protein (BCL9), drives oncogene expression in multiple cancers due to aberrent Wnt pathway signaling. Disruption of the P-catenin / BCL9 complex has been shown to suppress oncogenic Wnt / p-catenin transcription without impacting p- catenin homeostatic functions (Takada 2012).

[0003] In addition to its cell-autonomous mechanisms, deregulated Wnt / p-catenin signaling can promote tumorigenesis by impacting the tumor microenvironment. Reprogramming of immunosuppressive M2 -like Tumor Associated Macrophages (TAMs) toward an immune-promoting program (Ml -like) is an attractive cancer immunotherapeutic strategy (Sarode 2020). Wnt / p-catenin signaling may also impact the tumor microenvironment by decreasing regulatory T cells (Tregs); by suppressing CD8+ T cell activation via increased ATF3 expression, followed by subsequent downregulation of CCL2 / CCL4 in dendritic cells; or by modulating expression of CD155 (Feng 2019; Feng 2021).

[0004] ST316 is a novel peptide antagonist of P-catenin that specifically interferes with the association of -catenin and BCL9. disrupting p-catenin nuclear localization and attenuating target gene expression. In preclinical studies, including an orthotopic triplenegative breast cancer (TNBC) model, ST316 demonstrates potent anti -tumor activity, resulting in significant inhibition of tumor growth.SUMMARY OF THE INVENTION

[0005] Some of the main aspects of the present invention are summarized below.Additional aspects are described in the Detailed Description of the Invention. Examples,Drawings, and Claims sections of this disclosure. The description in each section of this disclosure is intended to be read in conjunction with the other sections. Furthermore, the various embodiments described in each section of this disclosure can be combined in various different ways, and all such combinations are intended to fall within the scope of the present invention.

[0006] The disclosure provides a combination approach for administering a peptide antagonist of P-catenin and an immunomodulator. In one embodiment, a method is provided for inhibiting growth of a solid tumor in a subject, the method comprising combination therapy with: (i) a pharmaceutical composition comprising an effective amount of a peptide antagonist of P-catenin and (ii) a pharmaceutical composition comprising an effective amount of an immunomodulator; wherein the pharmaceutical composition comprising the antagonist of P-catenin and the pharmaceutical composition comprising the immunomodulator are administered to the subject together or separately.

[0007] Another embodiment is a method of reducing solid tumor volume in a subject, the method comprising combination therapy with: (i) a pharmaceutical composition comprising an effective amount of a peptide antagonist of P-catenin and (ii) a pharmaceutical composition comprising an effective amount of an immunomodulator; wherein the pharmaceutical composition comprising the antagonist of P-catenin and the pharmaceutical composition comprising the immunomodulator are administered to the subject together or separately.

[0008] An additional embodiment provides a method of treating a solid tumor in a subject, the method comprising combination therapy with: (i) a pharmaceutical composition comprising an effective amount of a peptide antagonist of P-catenin and (ii) a pharmaceutical composition comprising an effective amount of an immunomodulator; wherein the pharmaceutical composition comprising the antagonist of P-catenin and the pharmaceutical composition comprising the immunomodulator are administered to the subject together or separately.

[0009] Also provided is a pharmaceutical composition comprising an effective amount of a peptide antagonist of P-catenin and a pharmaceutical composition comprising an effective amount of an immunomodulator for use in a method of combination therapy for inhibiting growth of a solid tumor in a subject, for reducing solid tumor volume in a subject, and / or for treating a solid tumor in a human subject.

[0010] In some embodiments, the solid tumor is breast cancer, colorectal cancer, cholangiocarcinoma, hepatocellular carcinoma, melanoma, non-small cell lung cancer, ovarian cancer, pancreatic adenocarcinoma, or synovial sarcoma. In particular embodiments, the subject has been diagnosed with a locally advanced or metastatic cancer.

[0011] In one embodiment, the peptide antagonist comprises the D-amino acid sequence FRWLLRQLARLAQLAKLTPVKLTPV (SEQ ID NO: 1). In some embodiments, the peptide antagonist is a cell -penetrating peptide. For example, the peptide antagonist can comprise a cell-penetrating sequence. In a particular embodiment, the peptide antagonist is ST316. In certain embodiments, the peptide antagonist disrupts binding of 0-catenin to B-cell CLL / lymphoma 9 protein (BCL9).

[0012] In some embodiments, the peptide antagonist is administered to the subject at a dose of about 0.25-12 mg / kg.

[0013] In a certain aspect of the invention, the immunomodulator is an antibody or an antibody-drug conjugate, for example, selected from the group consisting of amivantamab, belantamab mafodotin-blmf, bevacizumab, cetuximab, denosumab, dinutuximab. enfortumab vedotin-ejfv, margetuximab, naxitamab-gqgk, necitumumab. panitumumab, pertuzumab, ramucirumab, Sacituzumab govitecan-hziy, tebentafusp-tebn, tisotumab vedotin, trastuzumab, trastuzumab deruxtecan, and trastuzumab emtansine. In a particular aspect, the antibody is an anti-PD-1 antibody.

[0014] In one aspect of the invention, the immunomodulator is selected from the group consisting of a checkpoint inhibitor, a cytokine, an immune adjuvant. The checkpoint inhibitor can target, for example, at least one of PD-1, PD-L1, CTLA-4, LAG- 3, TIGIT, or VISTA. In particular embodiments, the checkpoint inhibitor is atezolizumab, avelumab, cemiplimab, dostarlimab, durvalumab, ipilimumab, nivolumab, pembrolizumab, relatimab. or a combination thereof.

[0015] In one embodiment, the immunomodulator is a cytokine that targets, for instance, at least one of the IL-2 pathway, the IL-2R pathway, the IFNAR1 pathway, or the IFNAR2 pathway. Examples of cytokines for use in the methods of the invention include aldesleukin, granulocyte-macrophage colony-stimulating factor, interferon alfa- 2a, interferon alfa-2b, and peginterferon alfa-2b.

[0016] The immunomodulator can be an immune adjuvant. Tn one embodiment, the immune adjuvant targets the Toll-like receptor 7 pathway or the Toll-like receptor 3 pathway. Particular examples of immune adjuvants include Imiquimod and Poly ICLC.

[0017] In a preferred embodiment, the antagonist of (3-catenin is ST316, and the immunomodulator is a PD-1 inhibitor, such as an anti-PD-1 antibody.

[0018] In one embodiment, the pharmaceutical composition comprising the antagonist of (3-catenin and / or the pharmaceutical composition comprising the immunomodulator is administered parenterally, for example, intravenously.

[0019] In some embodiments, the pharmaceutical composition comprising the antagonist of (3-catenin and the pharmaceutical composition comprising the immunomodulator are administered to the subject on different days.

[0020] In certain embodiments, the pharmaceutical composition comprising the antagonist of (3-catenin is administered once weekly for at least three weeks or once every two weeks for at least four weeks. In certain embodiments, the pharmaceutical composition comprising the immunomodulator is administered at least once weekly for at least three weeks, or once every7two weeks for at least four weeks, or once every three weeks for at least six weeks.BRIEF DESCRIPTION OF THE DRAWINGS

[0021] FIG. 1A-1D show that ST316 converts M2 -like macrophages to Ml-like phenotype. FIG. 1A shows an experimental outline of Ml and M2 macrophage establishment from hPBMCs. FIG. IB shows flow cytometry plots of macrophage cells in culture conditions that promote M2 differentiation at Day 10 at the indicated ST316 concentrations. Ml-like (CD68+CD1631ow) and M2-like (CD68dimCD163+) populations are indicated. FIG. 1C shows normalized hPBMCs M1 / M2 macrophage ratios from three unrelated donors at the indicated ST316 concentrations. FIG. ID shows flow cytometry7plots for the Ml Marker CD80 and CD163 in hPBMC-derived M2 Macrophages treated with the indicated ST316 concentrations.

[0022] FIG. 2A-2B show that ST316 increases macrophage-induced CD8+ T cell activation in M2 suppressive conditions. FIG. 2A shows CD8+ T cells co-cultured for 3 days with Ml or M2 macrophage and left untreated (0) or treated with 0.625 or 1.25 uM ST316 and anti-PD-1 (A-PD-1, 20 ng / mL), or isotype IgG4 Control (ISO). Flow cytometry plots for are CD8 and intracellular IFN-y. FIG. 2B shows the frequency of IFN-gamma producing CD8+ cells after 3 days in co-culture with Ml or M2macrophages at the indicated conditions. Arrows point to the comparison between M2 conditions in the absence or presence of 1.25 uM ST316, indicating a three-fold increase in IFN-y(+) cells. T-cell only conditions were assessed in duplicate

[0023] FIG. 3A-3C show that subtherapeutic ST316 potentiates response to anti-PD- 1 therapy in vivo in the orthotopic 4T1 Triple Negative Breast Cancer (TNBC) model. Balb / c mice harboring 4T1 tumors implanted into the 4th mammary fatpad were administered subtherapeutic ST316 (2mg / kg once weekly) subcutaneously and / or anti- PD-1 (BioXCell) intraperitoneally (FIG. 3A). Mean Tumor volumes are shown in FIG. 3B for the indicated treatment cohorts (n=5 / group). Error bars represent SEM. P-value statistics are one-way ANOVA for the indicated comparisons at Day 38 (n=5 / group; ****p<0.001; ***<p<0.01; **p<0.05). FIG. 3C shows a geometric means for expression of the M2 marker CD209a in TAMS (gated as CD45+;Grlint;F4 / 80+) isolated from tumors in the indicated cohorts (n=5 / group; *,p<0.05; one-way ANOVA).

[0024] FIG. 4A-4D show that ST316 increases surface expression of CD1 5 / PVR in P-catenin-dependent cell lines. FIG. 4A shows a proposed model for cooperation between ST316 and TIGIT checkpoint blockade. The left side (T-cell inactive) shows a schematic of the CD155 / TIGIT checkpoint. CD155 / PVR mediates activation of cytotoxic T-cells (CTL) by binding CD226. TIGIT binds competitively CD155 and suppresses T-cell activation. The right side (T-cell active) shows ST316-driven CD155 upregulation leading to increased T cell activity in the presence of TIGIT inhibition.FIG. 4B shows representative histograms (mode-normalized) for CD155 fluorescence for 4T1 cells untreated or treated with 2.5 uM ST316 for 48hrs. FIG. 4C shows Median Fluorescence Intensity (MFI) of CD 155 in the P-catenin-driven lines 4T1D (mouse TNBC), HCT116 (human colorectal cancer), and CT-26 (mouse colorectal cancer), untreated or treated at the indicated ST316 concentrations. (Statistics represent t-test of the indicated pair; ***,p<0.001; **,p<0.01; ns, not significant. One-way Anova. n=3 / group.) The melanoma cell line RVH-421, which is not considered to be P-catenin- driven, is shown as control. FIG. 4D shows that ST316 enhances CTL response in the presence of anti -TIGIT and anti-PD-1 antibodies. 4T1 cells were exposed for 24 hrs to ST316 and then incubated with CFSE-loaded CD8+ syngeneic T cells. After 4 days. T cells were recovered and the fraction of proliferative / static (P / S) culture was measured by comparing the non-proliferating T fraction (S) to the proliferating fraction (P). Statistics:****^0.0001; ***p<0.001, **p<0.01, *p<0.05 not significant. One-way Anova, n=4 / group. Comparisons that are not significant are not indicated.

[0025] FIG. 5A-5B show that ST316 suppresses PD1 in CD8+ T cells. CD8+ T cells from hPBMC were cultured in the presence of ST316 for 24 hrs. PD1 expression was determined by flow cytometry and is show n as percentage of the population (FIG. 5A) or MFI (FIG. 5B). Statistics: ****p<0.001, one-way Anova, n=3 / group.

[0026] FIG. 6A-6C show ST316-induced reduction of immune-suppressive polymorphonuclear (PMN) myeloid-derived suppressor cell (MDSC) population in cancer patients. Peripheral blood samples were collected from a patient with pancreatic ductal adenocarcinoma (PDAC) (FIG. 6A) or colorectal cancer (CRC) (FIG. 6B) before (top panels) and after treatment with 4 mg / kg ST316, QW for 3 weeks (bottom panels). Blood was processed to collect lymphocyte and myeloid cells and analyzed by flow cytometry. PMN cells (CD3-, CD19-. CD14-. HLADRlow. CDllb+ and CD15+) were quantified as a percentage of myeloid cells (CD3-, CD19-) (FIG. 6C).DETAILED DESCRIPTION OF THE INVENTION

[0027] In order that the present invention can be more readily understood, certain terms are first defined. Additional definitions are set forth throughout the disclosure. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention is related.

[0028] Any headings provided herein are not limitations of the various aspects or embodiments of the invention, which can be had by reference to the specification as a whole. Accordingly, the terms defined immediately below are more fully defined by reference to the specification in its entirety.

[0029] All references cited in this disclosure are hereby incorporated by reference in their entireties. In addition, any manufacturers’ instructions or catalogues for any products cited or mentioned herein are incorporated by reference. Documents incorporated by reference into this text, or any teachings therein, can be used in the practice of the present invention. Documents incorporated by reference into this text are not admitted to be prior art.I. Definitions

[0030] The phraseology or terminology in this disclosure is for the purpose of description and not of limitation, such that the terminology or phraseology of the present specification is to be interpreted by the skilled artisan in light of the teachings and guidance.

[0031] As used in this specification and the appended claims, the singular forms “a,” “an,” and “the” include plural referents, unless the context clearly dictates otherwise. The terms “a” (or “an”) as well as the terms “one or more” and “at least one” can be used interchangeably.

[0032] Furthermore, “and / or” is to be taken as specific disclosure of each of the two specified features or components with or without the other. Thus, the term “and / or” as used in a phrase such as “A and / or B” is intended to include A and B, A or B, A (alone), and B (alone). Likewise, the term “and / or” as used in a phrase such as “A, B, and / or C” is intended to include A, B, and C; A, B, or C; A or B; A or C; B or C; A and B; A and C; B and C; A (alone); B (alone); and C (alone).

[0033] Wherever embodiments are described with the language “comprising,” otherwise analogous embodiments described in terms of “consisting of’ and / or “consisting essentially of’ are included.

[0034] Units, prefixes, and symbols are denoted in their Systeme International d’ Unites (SI) accepted form. Numeric ranges are inclusive of the numbers defining the range, and any individual value provided herein can serve as an endpoint for a range that includes other individual values provided herein. For example, a set of values such as 1, 2, 3, 8, 9. and 10 is also a disclosure of a range of numbers from 1-10, from 1-8, from 3-9, and so forth. Likewise, a disclosed range is a disclosure of each individual value (z.e., intermediate) encompassed by the range, including integers and fractions. For example, a stated range of 5-10 is also a disclosure of 5, 6, 7, 8, 9, and 10 individually, and of 5.2, 7.5. 8.7, and so forth.

[0035] Unless otherwise indicated, the terms “at least” or “about” preceding a series of elements is to be understood to refer to every element in the series. The term “about” depends on the context in which it is used. When preceding a numerical value, it generally includes ± 10% of the recited value. For example, in one context, a concentration of about 1 mg / mL includes 0.9 mg / mL to 1. 1 mg / mL. Likewise, a concentration range of about 1% to 10% (w / v) can include 0.9% (w / v) to 11% (w / v).

[0036] The terms “polypeptide,” “peptide,” and “protein” are used interchangeably to refer to polymers of amino acids of any length, and their salts. The polymer can be linear or branched, can comprise modified amino acids, and can be interrupted by non-amino acids. Except where indicated otherwise, e.g. . for the abbreviations for the uncommon or unnatural amino acids set forth herein, the three-letter and one-letter abbreviations, as used in the art, are used herein to represent amino acid residues. Except when preceded with a “D” or in lower case, the amino acid is an L-amino acid. Groups or strings of amino acid abbreviations are used to represent peptides. Except where specifically indicated, peptides are indicated with the N-terminus of the left and the sequence is written from the N-terminus to the C-terminus.

[0037] A “retro inverse” peptide has a reversed amino acid sequence, relative to a reference L-amino acid sequence, and is made up of all D-amino acids (inverting the a- center chirality of the amino acid subunits) to help maintain side-chain topology similar to that of the original L-amino acid peptide.

[0038] An “isolated” molecule is one that is in a form not found in nature, including those which have been purified.

[0039] An “active agent” is an ingredient that is intended to furnish biological activity. The active agent can be in association with one or more other ingredients. An active agent that is a peptide can also be referred to as an “active peptide.”

[0040] An “effective amount” of an active agent is an amount sufficient to cany out a specifically stated purpose.

[0041] The term “pharmaceutical composition” refers to a preparation that is in such form as to permit the biological activity of the active ingredient to be effective and which contains no additional components that are unacceptably toxic to a subject to which the composition would be administered. Such composition can be sterile and can comprise a pharmaceutically acceptable carrier, such as physiological saline. Suitable pharmaceutical compositions can comprise one or more of a buffer e.g., acetate, phosphate, or citrate buffer), a surfactant (e g. , polysorbate), a stabilizing agent (e.g , polyol or amino acid), a preservative (e.g, sodium benzoate), and / or other conventional solubilizing or dispersing agents.

[0042] A “subject” or “individual” or “animal” or “patient” or “mammal.” is any subject, particularly a mammalian subject, for whom diagnosis, prognosis, or therapy is desired. Mammalian subjects include humans, domestic animals, farm animals, sportsanimals, and laboratory animals including, e.g., humans, non-human primates, canines, felines, porcines, bovines, equines, rodents, including rats and mice, rabbits, etc.

[0043] A “control patient’' is a subject that has not received a treatment of the invention. A “control population” or a “population of control patients” is a group of subjects that have not received a treatment of the invention. A control patient or subject in the control population has the same disease or disorder as the subject being compared to the control patient or control population. For example, a clinical outcome of a cancer patient receiving the compositions or method of the invention is compared with the average (median) outcome of subjects having the same type of cancer who did not receive a pharmaceutical composition or method of the invention. In some embodiments, the control patient or patients in the control population have received a treatment other than a treatment of the invention, for example, a standard-of-care treatment.

[0044] Terms such as “treating” or “treatment” or “to treat” or “alleviating” or “to alleviate” refer to therapeutic measures that cure, slow down, lessen symptoms of, and / or halt progression of a diagnosed pathologic condition or disorder. In certain embodiments, a subject is successfully “treated” for a disease or disorder if the patient shows total, partial, or transient alleviation or elimination of at least one symptom or measurable physical parameter associated with the disease or disorder.

[0045] An “antagonist” is a substance that prevents, blocks, inhibits, neutralizes, or reduces a biological activity or effect of another molecule, such as a receptor or ligand.

[0046] The terms “inhibit,” “block,” and “suppress” are used interchangeably and refer to any statistically significant decrease in occurrence or activity, including full blocking of the occurrence or activity. For example, “inhibition” can refer to a decrease of about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100% in activity or occurrence. An “inhibitor” is a molecule, factor, or substance that produces a statistically significant decrease in the occurrence or activity of a process, pathway, or molecule.

[0047] A “tumor” or “solid tumor” is a mass of neoplastic cells, such as cancer cells. The terms “advanced,” “metastatic,” and “advanced / metastatic” are used interchangeably to describe a cancer in which malignant cells have migrated from the original tumor to another location, for example, another organ, in a patient's body.

[0048] A “neoplastic cell” or “neoplasm” typically has undergone some form of mutation / transformation, resulting in abnormal growth as compared to normal cells or tissue of the same type. Neoplasms include morphological irregularities, as well aspathologic proliferation. Neoplastic cells can be benign or malignant. Malignant neoplasms, / .<?. , cancers, are distinguished from benign in that they demonstrate loss of differentiation and orientation of cells, and have the properties of invasion and metastasis.II. PeptidesP-Catemn

[0049] The Wnl / -calenin pathway is a validated target for cancer therapies. Constitutive activation of the Wnt / p-catenin signaling pathway is implicated in carcinogenesis, tumor progression, and poor prognosis of many malignancies (Shang 2017). The complex formed by the interaction between p-catenin and its co-activator, BCL9, drives oncogene expression in multiple cancers due to aberrent Wnt pathway signaling. Disruption of the P-catenin / BCL9 complex has been show n to suppress oncogenic Wnt / p-catenin transcription without impacting P-catenin homeostatic functions (Takada 2012).

[0050] The interaction between p-catenin and BCL9 has previously been considered an ■■undruggable” target due to the inability of small molecules to inhibit complex formation and the inability of antibodies to gain access to the cytoplasm or nucleus to disrupt the interaction (Takada 2012). Peptide antagonism of P-catenin is distinct from these other approaches because it can specifically target the interaction between p-catenin and BCL9 and is selectively toxic to tumor cells where these proteins are hyperactive.P-Catenin Antagonist Peptides

[0051] In some embodiments, methods of the invention comprise treating a patient having a solid tumor with combination therapy comprising an effective amount of a peptide antagonist of P-catenin and an immunomodulator. Preferably, the peptide antagonist of P-catenin disrupts interaction of P-catenin with BCL9. Peptide antagonists of P-catenin can be rationally designed, for example, based on the native sequence of BCL9 with modifications to enhance electrostatic interactions between the peptide antagonist and P-catenin. In particular, peptide antagonists of the interaction between P- catenin and BCL9 can be derived from the homology domain 2 (HD2) of BCL9 and designed to interact with the first armadillo repeat (ARM-1) domain of P-catenin, which is a site utilized by BCL9 but not other P-catenin binding partners. WO 2021 / 007158 provides numerous examples of such peptides.

[0052] The ability of a peptide based on wild-type BCL9 to antagonize the activity of P-catenin, such as to disrupt the interaction of -catenin with BCL9, can be measured by methods described herein, for instance, in Example 1. The cytotoxic activity of a peptide antagonist of P-catenin can be measured in vitro by known assays and / or in vivo using known tumor models: for example, WO 2019 / 136125 and WO 2021 / 007158 describe such assays and models.

[0053] The peptide antagonist of P-catenin can be a cell-penetrating peptide. In one embodiment, the peptide comprises a cell-penetrating domain. Numerous cellpenetrating peptide sequences are described and characterized in the literature (see WO 2019 / 136125). In one embodiment, the peptide is a cyclic peptide. Cyclized peptides, for example, using hydrocarbon staples (Bemal 2007; Bird 2017) or other cyclization methods known in the art, can enter cells via passive diffusion, endocytosis / endosomal escape, or other mechanisms (Dougherty 2019). Peptides can also be delivered to cells via mechanisms that exploit cellular receptors, for example, integrin-targeting, RGD-like sequences. Alternatively, peptides can be encapsulated and delivered to cells in vesicles, such as exosomes or liposomes, or in micelles.

[0054] ST316 is a novel 25-amino acid peptide antagonist of the interaction between P-catenin and BCL9. ST316 is composed entirely of D-amino acids and is highly stable in the presence of proteolytic enzymes. Due to its resistance to protease degradation, ST316 has a long plasma half-life, and should not be processed and presented by antigen presenting cells, thereby avoiding stimulation of an anti-drug antibody (ADA) response.

[0055] ST316 is composed of two domains: (i) a 15 amino acid N-terminal active domain derived from the homology domain 2 (HD2) of BCL9 and designed to interact with the first armadillo repeat (ARM-1) domain of P-catenin, which is a site utilized by BCL9 but not other P-catenin binding partners; and (ii) a 10 amino acid C-terminal domain, which increases solubility and cell penetration. The D-amino acid sequence of ST316 is: FRWLLRQLARLAQLA Z W 7 E(SEQ ID NO: 1). The N-terminal active domain is bolded and the C-terminal cell -penetrating domain is italicized. ST316 also comprises an N-terminal octanoyl group.

[0056] We demonstrate for the first time that ST316 alters the tumor microenvironment by reprograming macrophage differentiation to an Ml phenotype and modulating expression of tumor cell surface markers that interact with checkpoint molecules on immune cells. The potential effect of ST316 on antitumor immunity led usto test whether the combination of a P-catenin antagonist, such as ST31 , and an immunomodulator, such as an immune checkpoint inhibitor, would result in enhanced anti -tumor activity. The combination of ST316 and PD-1 unexpectedly reduced tumor volume in a mouse model of triple-negative breast cancer, demonstrating significantly improved activity over either active agent alone. (See Example 3; FIG. 3B-3C).Methods of Preparing B-Catenin Antagonists

[0057] Peptide antagonists of p-catenin can be chemically synthesized, for example, using solid-phase peptide synthesis or solution-phase peptide synthesis, or a combination of both. Synthesis may optionally occur as fragments of the peptide that are subsequently combined either chemically or enzymatically.

[0058] Alternatively, peptide antagonists of P-catenin can be expressed using recombinant methods. For example, nucleic acid molecules encoding ST316 can be constructed by chemical synthesis using an oligonucleotide synthesizer. Nucleic acid molecules can be designed based on the amino acid sequence of ST316 and selection of those codons that are favored in the host cell in which the recombinant ST316 will be produced. Standard methods can be applied to synthesize a nucleic acid molecule encoding a peptide antagonist of P-catenin, such as ST316.

[0059] Once prepared, the nucleic acid encoding the peptide can be inserted into an expression vector and operably linked to an expression control sequence appropriate for expression of the peptide in a desired host. In order to obtain high expression levels of the peptide, the nucleic acid can be operably linked to or associated with transcriptional and translational expression control sequences that are functional in the chosen expression host.

[0060] A wide variety of expression host / vector combinations can be employed to anyone known in the art. Useful expression vectors for eukaryotic hosts include, for example, vectors comprising expression control sequences from SV40, bovine papilloma virus, adenovirus, and cytomegalovirus. Useful expression vectors for bacterial hosts include known bacterial plasmids, such as plasmids from E. coli, including pCRl, pBR322, pMB9 and their derivatives, wider host range plasmids, such as M13, and filamentous single-stranded DNA phages.

[0061] Suitable host cells include prokaryotes, yeast, insect, or higher eukaryotic cells under the control of appropriate promoters. Prokary otes include gram negative or gram positive organisms, for example E. coli or bacilli. Higher eukaryotic cells can beestablished or cell lines of mammalian origin, examples of which include Pichia pastoris, 293 cells, COS-7 cells, L cells, C127 cells, 3T3 cells, Chinese hamster ovary (CHO) cells, HeLa cells, and BHK cells. Cell-free translation systems can also be employed.

[0062] Peptides can be purified using methods that include, for example, reversephase high-performance liquid chromatography (RP-HPLC), multicolumn countercurrent solvent gradient purification (MCSGP), and ion-exchange chromatography.III. Immunomodulators

[0063] The methods of the invention involve combination therapy comprising administration of a [3-catenin antagonist and an immunomodulator. The terms “immunomodulator,” “immunomodulating agent,” and “immunotherapeutic agent” are interchangeable and refer to an active agent that stimulates or suppresses the immune system of a subject to fight a disease or infection. In the context of the present invention, the disease is a neoplasia or cancer.

[0064] Immunomodulators include, for example, immune checkpoint inhibitors; cytokines; targeted antibodies and drug-antibody conjugates; adjuvants, such as imiquimod and polyinosinic-poly cytidylic acid (poly ICLC); oncolytic viruses, such as T- VEC; and small molecule drugs, such as thalidomide, lenalidomide, or pomalidomide.

[0065] Immune checkpoint inhibitors target immune checkpoint proteins or their ligand(s). Immune checkpoint proteins include, but are not limited to, cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), also known as CD 152; programmed cell death protein 1 (PD-1), also known as CD279; lymphocyte-activation gene 3 (LAG-3), also known as CD223; T cell immunoglobulin mucin (TIM-3), also known as HAVcr2; T cell immunoreceptor with Ig and ITIM domains (TIGIT), also known as WUCAM and Vstm3; and V-domain Ig suppressor of T cell activation (VISTA). Examples of immune checkpoint inhibitors include atezolizumab, avelumab, cemiplimab, dostarlimab, durvalumab, ipilimumab, nivolumab, pembrolizumab, and relatlimab.

[0066] Some cytokines, such as interferons, can disrupt the division of cancer cells and slow tumor growth. Other cytokines, such as interleukins (IL), stimulate immune cell growth and proliferation. Examples of immunomodulating cytokines include aldesleukin, granulocyte-macrophage colony -stimulating factor, interferon alfa-2a, interferon alfa-2b, and peginterferon alfa-2b.

[0067] Targeted antibodies can be customized to target antigens on the surface of cancer cell, in order to disrupt cancerous activity, particularly unrestrained growth. Some targeted antibodies are conjugated to anti-cancer drugs. Other targeted antibodies are bispecific, for example, binding both cancer cells and T cells in order to enhance the anticancer immune response. Examples of targeted antibodies and drug-antibody conjugates include amivantamab, belantamab mafodotin-blmf, bevacizumab, cetuximab, denosumab, dinutuximab, enfortumab vedotin-ejfv, margetuximab, naxitamab-gqgk, necitumumab, panitumumab, pertuzumab, ramucirumab, Sacituzumab govitecan-hziy. tebentafusp-tebn, tisotumab vedotin, trastuzumab, trastuzumab deruxtecan, and trastuzumab emtansine.IV. Compositions and Administration

[0068] In certain aspects, the invention provides a combination approach comprising administration of a composition, e.g., a pharmaceutical composition, comprising an effective amount of a peptide antagonist of 0-catenin, such as ST316, and administration of composition, e.g., a pharmaceutical composition, comprising an effective amount of an immunomodulating agent, such as a checkpoint inhibitor.

[0069] Because the combination therapy of the invention demonstrates synergism between the 0-catenin antagonist and the immunomodulator, the effective amount of each active agent can, in some embodiments, be lower than the effective amount when each active agent is administered individually. For example, the effective amount of each of the peptide antagonist of 0-catenin and the immunomodulating agent may be a sub- therapeutic dose.

[0070] The peptide antagonist of 0-catenin can be dosed based on the patient's weight. The peptide antagonist of 0-catenin, such as ST316, can be administered to a patient at a dose of about 0.25 mg / kg to about 12 mg / kg. In certain embodiments, ST316 is administered at a dose of about 0.25 mg / kg, about 0.5 mg / kg, about 0.75 mg / kg, about 1 mg / kg, about 1.5 mg / kg, about 2 mg / kg, about 2.5 mg / kg, about 3 mg / kg. about 3.5 mg / kg. about 4 mg / kg. about 4.5 mg / kg. about 5 mg / kg. about 5.5 mg / kg. about 6 mg / kg, about 6.5 mg / kg, about 7 mg / kg, about 7.5 mg / kg, about 8 mg / kg, about 9 mg / kg, about 10 mg / kg, about 11 mg / kg, or about 12 mg / kg. These amounts can also serve as endpoints for a range of doses to be administered, for example, about 0.75 mg / kg to about 7 mg / kg, about 2 mg / kg to about 4 mg / kg. etc.

[0071] Alternatively, the peptide antagonist of P-catenin can be administered at a fixed dose. The peptide antagonist of P-catenin, such as ST316, can be administered to a patient at a dose of about 500 mg to about 1500 mg. In certain embodiments, ST316 is administered at a dose of about 500 mg, about 550 mg, about 600 mg, about 650 mg. about 700 mg, about 750 mg, about 800 mg, about 850 mg, about 900 mg, about 950 mg, about 1000 mg, about 1100 mg, about 1200 mg, about 1300 mg, about 1400 mg, or about 1500 mg. These amounts can also serve as endpoints for a range of doses to be administered, for example, about 600 ng to about 1100 mg, about 750 mg to about 900 mg. etc.

[0072] The compositions are preferably administered parenterally. Parenteral routes of administration include intravenous (IV), intramuscular, intraperitoneal, intrathecal, and subcutaneous. In certain embodiments the composition comprising the peptide antagonist of -catenin and / or the composition comprising the immunomodulator are / is administered to the subject by intravenous infusion.

[0073] The composition comprising a peptide antagonist of P-catenin and the composition comprising an immunomodulator can be the same composition or can be different compositions. If the peptide antagonist and the immunomodulating agent are comprised in two separate compositions, the two compositions can be administered to the subject at the same time or at different times, including on different days.

[0074] Each of the composition comprising a peptide antagonist and the composition comprising an immunomodulator is administered to the subject more than once. In one embodiment, administration of the peptide antagonist of P-catenin can occur once weekly for a duration of at least one week (z.e., one administration), at least two weeks (z.e., two administrations), at least three weeks (z. e. , three administrations), at least six weeks (z. e. , six administrations), at least nine weeks, at least twelve weeks, at least three months, at least six months, at least nine months, or at least twelve months. In another embodiment, administration can occur once every two weeks for a duration of at least four weeks (i.e. , two administrations), at least eight weeks (i.e., four administrations), at least twelve weeks, at least three months, at least six months, at least nine months, or at least twelve months. In some embodiments, a patient can be administered the peptide antagonist of P- catenin once weekly for a duration of at least one week, two weeks, three weeks, six weeks, nine weeks, twelve weeks, three months, six months, nine months, or twelvemonths, followed by administration once every two weeks for at least four weeks, eight weeks, twelve weeks, three months, six months, nine months, or twelve months.

[0075] In one embodiment, administration of the immunomodulator can occur at least once weekly for a duration of at least three weeks (z.e., three administrations), six weeks (z.e., six administrations), nine weeks, twelve weeks, three months, six months, nine months, or twelve months. In another embodiment, administration can occur once every two weeks for a duration of at least four weeks (z.e., two administrations), eight weeks (z.e., four administrations), twelve weeks, three months, six months, nine months, or twelve months. In a further embodiment, administration of the immunomodulator can occur once every three weeks for a duration of at least six weeks (z. e. , two administrations), nine weeks (z. e. , three administrations), twelve weeks, three months, six months, nine months, or twelve months. In an additional embodiment, administration of the immunomodulator can occur once every four weeks for a duration of at least eight weeks (z.e. , two administrations), twelve weeks (z.e., three administrations), three months, six months, nine months, or twelve months. Likewise, administration of the immunomodulator can occur once a month for a duration of at least two months (z. e. , two administrations), three months (z. e. , three administrations), six months, nine months, or twelve months.

[0076] For purposes of the present disclosure, “combination therapy” means that the treatment period comprising administration of the peptide antagonist of 0-catenin overlaps with the treatment period comprising administration of the immunomodulator.

[0077] Neoadjuvant therapy can be administered to reduce the size or extent of a tumor, or to make a subsequent treatment easier, more effective, or less extensive. In a particular embodiment, the peptide antagonist of 0-catenin can be administered as a neoadjuvant prior to, for example, surgery and / or radiation.V. Methods of Use

[0078] Subjects in need of the methods of the invention are patients diagnosed with a solid tumor. For example, the subject can have a locally advanced solid tumor or a metastatic inoperable tumor or an advanced unresectable tumor. In one embodiment, the tumor harbors one or more abnormalities in the Wnt / 0-catenin signaling pathway. By way of non-limiting example, the one or more abnormalities in the Wnt / 0-catenin signaling pathway can comprise one or more mutations in one or more of adenomatouspolyposis coli (APC), APC membrane recruitment protein 1 (AMER1 ), Axin2, 0-catenin, RING finger protein 43 (RNF43), and / or T cell factor 7 (TCF7).

[0079] In some embodiments, the subject has basal cell carcinoma, bladder cancer, breast cancer (including triple-negative breast cancer), cervical cancer, cholangiocarcinoma, colorectal cancer, endometrial cancer, esophageal cancer, gastric cancer, hepatocellular carcinoma, head and neck cancer, Merkel cell carcinoma, melanoma, non-small cell lung cancer, ovarian cancer, pancreatic adenocarcinoma, renal cell carcinoma, squamous cell carcinoma, synovial sarcoma, or urothelial cell carcinoma.

[0080] In particular embodiments of the invention, combination therapy with a peptide antagonist of 0-catenin, such as ST316, and an immunomodulator can inhibit tumor growth, reduce tumor volume, or a combination thereof.

[0081] Efficacy of treatment can be evaluated by one or more known measures. For example, patients subjected to methods of the invention can experience outcomes including extended survival, improved progression-free survival, improved duration of response, longer remission, reduced risk of relapse, and / or improved tumor response to treatment with the combination therapy of the invention, compared with the same outcome(s) in patients not subjected to methods of the invention, z.e., control patients. An outcome in a patient treated by a method of the invention can be compared, for example, to the median outcome in a population of control patients. The population of control patients can be administered, for example, a regimen selected from the group consisting of a placebo, surgery, radiation, chemotherapy, immunotherapy, hormone-based therapy, or targeted therapy. In another embodiment, a patient subjected to the combination therapy of the invention can be compared to a population of control patients administered treatment with only one of a peptide antagonist of 0-catenin or an immunomodulator. Comparisons can be analyzed statistically using, for example, the Wilcoxon signed rank test or the Kaplan-Meier method.

[0082] Tumor response to treatment can be assessed, for example, by measuring tumor burden and / or tumor regression. Response to treatment compares one or more measures of efficacy after a treatment regimen, as compared to baseline, e.g., prior to treatment with combination therapy. A baseline assessment is preferably performed within 24, 48, or 72 hours, or within 1, 2, 3, or 4 weeks prior to the first treatment. In a one preferred embodiment, a baseline assessment is performed within one week prior to the first ST316 treatment.

[0083] ’‘Tumor burden” is the total mass or total size of cancerous tissue in a patient’s body. Tumor response can be evaluated by measures including objective response rate, including partial response and / or complete response, stable disease, disease control rate, duration of disease control, and duration of response. Depending on the type of tumor, these parameters can be determined, for example, by revised Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (Eisenhauer 2009), by modified response assessment in neuro-oncology (mRANO) (Ellingson 2017), or by PCWG3 guidelines (Scher 2016).

[0084] Objective response rate assesses reduction of tumor size, for example, tumor diameter, which can be determined by clinical examination and / or imaging. Where a patient has multiple tumors, tumor size can optionally be expressed as the average diameter of all tumors or by the sum of diameters of all tumors. Superficial tumors can be measured clinically, for instance, using calipers or by photography and ruler measurement. Imaging methods include computed tomography (CT), typically with contrast; X-ray; magnetic resonance imaging (MRI); and positron emission tomography (PET), such as (18)F-fluorodeoxyglucose PET. In one preferred embodiment, CT is utilized to assess tumor response. Accordingly, in one aspect, the invention provides a method of reducing tumor burden, i.e., tumor mass and / or tumor size, in a patient, the method comprising administering to the patient combination therapy comprising a peptide antagonist of (3-catenin, such as ST316, and an immunomodulator. Reduction in tumor burden is measured relative to baseline.

[0085] In certain embodiments, particularly those in which assessment is by RECIST 1.1, disease control rate defines the level of tumor response as the best of the following: complete response (CR), which is the disappearance of tumor(s); partial response (PR), which is a decrease of at least 30%, in the size of tumor(s); stable disease (SD), in which the change in tumor size is decreased by less than 30% or increased by less than 20%; or disease progression, which is an increase of at least 20%, in tumor size and / or new lesions. Patients treated by methods of the invention can experience CR, PR, or SD.

[0086] Duration of disease control is the length of time from achievement of a response (CR or PR) or SD until disease progression. Duration of response is the length of time from the achievement of a response until disease progression, i.e., the period in which a tumor does not grow or spread, or death. Duration of response in patients receiving combination therapy of the invention can be, for example, at least 4, 6, 8, 10, or12 weeks, at least 4, 6, 8, 10, 12, 16, 18, or 24 months, or at least 3, 4, or 5 years. Patients treated by methods of the invention can experience increased duration of disease control or increased duration of response. Accordingly, in one aspect, the invention provides a method of increasing the duration of response in a patient, the method comprising administering to the patient combination therapy comprising a peptide antagonist of 0- catenin and an immunomodulator. Increase in duration of disease control or duration of response is measured relative to the median duration of disease control or duration of response, respectively, in a control population.

[0087] Survival can be assessed as overall survival, i. e.. the length of time a patient lives, as progression-free survival, z.e., the length of time a patient is treated without progression or worsening of the disease, or as event-free survival, i.e., the length of time that a patient remains free of complications or negative events such as relapse or disease progression. Survival is from the date that treatment commences. Overall survival, median overall survival, progression-free survival, median progression-free survival, event-free survival, and median event-free survival can be calculated, for example, by Kaplan-Meier analysis, based on the response to treatment.

[0088] Accordingly, in one aspect, the invention provides a method of increasing overall survival in a patient, the method comprising administering to the patient combination therapy comprising a peptide antagonist of 0-catenin and an immunomodulator. Increase in overall survival can be measured relative to the median overall survival in a control population. Alternatively, an increase compared to a control population in the percentage of patients who survive for a given time period (e.g, 6 months or 12 months) indicates an increase in overall survival.

[0089] In another aspect, the invention provides a method of increasing progression- free survival in a patient, the method comprising administering to the patient combination therapy comprising a peptide antagonist of 0-catenin and an immunomodulator. Increase in progression-free survival can be measured relative to the median progression-free survival in a control population. Alternatively, an increase compared to a control population in the percentage of patients who are relapse-free for a given time period (e.g., 6 months or 12 months) indicates an increase in progression-free survival.

[0090] In a further aspect, the invention provides a method of increasing event-free survival in a patient, the method comprising administering to the patient a peptide antagonist of 0-catenin and an immunomodulator. Increase in event-free survival ismeasured relative to the median event-free survival in a control population. Alternatively, an increase compared to a control population in the percentage of patients who are event-free for a given time period (e.g, 6 months or 12 months) indicates an increase in event-free survival.

[0091] A patient is successfully treated according to the methods of the invention if the patient experiences or displays at least one of the following outcomes after administration of combination therapy:- undetectability of the tumor (or at least one tumor, if multiple tumors are present at baseline);- at least about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% reduction in tumor size compared to baseline;- no significant increase (e.g., less than 20% or less than 30%) in tumor size compared to baseline;- significantly increased duration of response, optionally compared with median duration of response of a population of control patients;- significantly increased progression-free survival, optionally compared with median progression-free survival of a population of control patients;- significantly increased overall survival, optionally compared with median overall survival of a population of control patients.EXAMPLES

[0092] Embodiments of the present disclosure can be further defined by reference to the following non-limiting examples. It will be apparent to those skilled in the art that many modifications, both to materials and methods, can be practiced without departing from the scope of the present disclosure.Example 1. P-Catenin Antagonist Reprograms Macrophage Repolarization

[0093] To explore the potential for a P-catenin antagonist to repolarize macrophages toward the Ml -like phenotype, primary human macrophages were cultured from peripheral blood mononuclear cells (hPBMCs) and activated toward the Ml or M2 phenotype by lipopolysaccharide (LPS) and TNFa (Ml) or IL-4 (M2), respectively, in the presence of ST316 (FIG. 1A).

[0094] Expression of macrophage markers indicating Ml (CD80, CD86, HLA-DR) and M2 (CD163, CD206, CD209) phenotype was analyzed by flow cytometry.Treatment with pharmacologically relevant concentrations of ST316 (0.625, 1.25 or 2.5pM) resulted in dose-dependent reduction in M2+ macrophages and corresponding induction of M1+ macrophages (FIG 1B-1D). In particular, ST316 treatment dose- dependently suppressed expression of the M2 marker CD 163 by flow cytometry, resulting in 100-fold increase in the M1 / M2 ratio without substantial impact on cell viability. Importantly, activation markers associated with Ml -state (CD80, CD86), and T-cell viability were not affected by ST316 at the concentrations used in these studies.Example 2. P-Catenin Antagonist Activates CD8+ T-Cells

[0095] Human T cells were co-cultured with Ml or M2 macrophage culture for three days. T cell activation was measured in CD8+ cells by intracellular interferon-gamma staining. In the presence of M2 macrophages. T cell activation was suppressed, as indicated by reduced percentage of interferon-gamma positive cells. Addition of ST316, with or w ithout anti-PD-1 antibody, to a culture of human T cells w ith M2 macrophages restored T cell activity. In particular, ST316 exposure resulted in a three-fold increase in T-cell activation compared to untreated in M2 / T cell co-cultures. Results are shown in FIG. 2A-2BExample 3. p-Catenin Antagonist and Checkpoint Inhibitor Show Anti- Tumor Activity

[0096] Using a syngeneic mouse model of triple-negative breast cancer (TNBC), we show that inhibition of P-catenin and PD-1 results in enhanced anti -tumor activity, compared with either treatment alone. Briefly , 4Tl-luc TNBC tumor cells were implanted orthotopically into the mammary fatpad of immune-competent Balb / c mice. Tumors reached approximately 100 mm3on day 10 post-implantation, when treatment was initiated. Animals received 2 mg / kg ST316 subcutaneously and / or 12 mg / kg anti- PD-1 antibody (BioXCell, Lebanon, NH) intraperitoneally once w eekly starting at day 11 post-tumor inoculation (FIG. 3A). Results demonstrate that ST316 enhances the antitumor activity of anti-PD-1 by increasing the M1 / M2 ratio. The combination of the P- catenin antagonist and checkpoint inhibitor increased inhibition of tumor growth (observed 85% vs. 51% with anti-PDl alone, p<0.01; vs. -9% with subtherapeutic ST316 alone, p<0.001) (FIG. 3B), and suppressed the expression of the M2 marker CD209a in TAMS isolated from the tumors for the indicated cohorts (n=5 / group: *,p<0.05;one-way ANOVA). (FIG. 3C). TAMS were gated as CD45+;Grlint;F4 / 80+.Example 4. P-Catenin Antagonist Increases Expression of Checkpoint Activators

[0097] CD 155, also known as poliovirus receptor (PVR) is a transmembrane protein that is involved in establishing junctions between epithelial cells. It is overexpressed in certain cancers, and forms an immune checkpoint with TIGIT, an inhibitory receptor expressed on certain immune cells, including CD8+ (cytotoxic) T cells. FIG. 4A show's a schematic of the mechanism by which CD155 / PVR mediates cytotoxic T cell activation and a model for cooperation between ST316 and TIGIT checkpoint blockade.

[0098] Human HCT116 colorectal carcinoma cells harbor a gain-of-function mutation in [3-catenin, and mouse CT-26 colorectal cancer cells also express elevated levels of - catenin. Treatment of HCT116 and CT-26 cells with ST316 for 48 hours increased surface expression of CD155, relative to untreated cells. Results are shown in FIG. 4B- 4C. Treatment with ST316 also increases T-cell activation in the presence of anti -TIGIT and / or anti-PD-1 antibodies in a co-culture assay (FIG. 4D), and leads to a decrease of PD-L1 in the immunosuppressive hPBMC-derived M2-L populations (FIG. 5A-5B).

[0099] These data support a model in which ST316 promotes a shift in the tumor microenvironment via multiple mechanisms, including driving macrophage polarization toward an immune-promoting phenotype, augmenting activity’ of cytotoxic T cells and increasing expression of checkpoint activators, such as CD155 / PVR, in cancer cells.Example 5. P-Catenin Antagonist Reduces PMN-MDSC Population in Patients

[0100] Patients with solid tumors were administered 4 mg / kg ST316 once weekly via intravenous infusion for nine weeks. Blood samples from a patient with pancreatic ductal adenocarcinoma and from a patient with colorectal cancer w ere collected before and after administration of ST316 and analyzed for immune cell populations. ST316 treatment resulted in reduction of the immune-suppressive polymorphonuclear (PMN) myeloid- derived suppressor cell (MDSC) population (FIG. 6A-6C). PMN-MDSC exhibit a CD3- CD19-CD 14-HLADRlowCD 11 b+CD 15+ phenotype.

[0101] These results indicate that ST316 blocks differentiation to the PMN-MDSC phenotype and demonstrate a physiological effect of ST316 on immune cells and support a role for combination therapy with an immunomodulator.REFERENCESBemal F. et al. Reactivation of the p53 Tumor Suppressor Pathway by a Stapled p53 Peptide. J. Am. Chem. Soc. 2007; 129:2456-2457.Bird GH, et al. Biophysical Determinants for Cellular Uptake of Hydrocarbon-Stapled Peptide Helices. Nat. Chem. Biol. 2017; 12:845-852.Dougherty PG, et al. Understanding Cell Penetration of Cyclic Peptides. Chem. Rev. 2019; 1 19(17): 10241-10287.Eisenhauer EA, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45(2):228-247.Ellingson B, et al. Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials. Neurotherapeutics. 2017; 14:307-320.Feng M, et al. Pharmacological inhibition of P-catenin / BCL9 interaction overcomes resistance to immune checkpoint blockades by modulating Tregcells. Sci. Adv. 2019; 5:eaau5240Feng M, et al. BCL9 regulates CD226 and CD96 checkpoints in CD8+ T cells to improve PD-1 response in cancer. Signal Transduction and Targeted Therapy. 2021; 6:313.Sarode P, et al. Reprogramming of tumor-associated macrophages by targeting P- catenin / FOSL2 / ARID5A signaling: A potential treatment of lung cancer. Sci. Adv. 2020; 6:eaaz6106.Scher HI, et al. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations from the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncology. 2016:34(12): 1402-1418.Shang S, et al. The regulation of P-catenin activity and function in cancer: therapeutic opportunities. Oncotarget 2017;8(20):33972-33989.Takada K, et al. Targeted disruption of the BCL9 / p-catenin complex inhibits oncogenic Wnt signaling. Sci Transl Med. 2012 Aug 22;4(148).***The present invention is further described by the following claims.

Claims

CLAIMS1. A method of inhibiting growth of a solid tumor in a subject, the method comprising combination therapy with: (i) a pharmaceutical composition comprising an effective amount of a peptide antagonist of p-catenin and (ii) a pharmaceutical composition comprising an effective amount of an immunomodulator; w herein the pharmaceutical composition comprising the antagonist of P-catenin and the pharmaceutical composition comprising the immunomodulator are administered to the subject together or separately.

2. A method of reducing solid tumor volume in a subject, the method comprising combination therapy with: (i) a pharmaceutical composition comprising an effective amount of a peptide antagonist of P-catenin and (ii) a pharmaceutical composition comprising an effective amount of an immunomodulator; wherein the pharmaceutical composition comprising the antagonist of P-catenin and the pharmaceutical composition comprising the immunomodulator are administered to the subject together or separately.

3. A method of treating a solid tumor in a subject, the method comprising combination therapy with: (i) a pharmaceutical composition comprising an effective amount of a peptide antagonist of P-catenin and (ii) a pharmaceutical composition comprising an effective amount of an immunomodulator; wherein the pharmaceutical composition comprising the antagonist of P-catenin and the pharmaceutical composition comprising the immunomodulator are administered to the subject together or separately.

4. The method of claim 1, wherein the solid tumor is a selected from the group consisting of breast cancer, colorectal cancer, cholangiocarcinoma, hepatocellular carcinoma, melanoma, non-small cell lung cancer, ovarian cancer, pancreatic adenocarcinoma, and synovial sarcoma.

5. The method of claim 1. wherein the peptide antagonist disrupts binding of P- catenin to B-cell CLL / lymphoma 9 protein (BCL9).

6. The method of claim 1, wherein the peptide antagonist comprises the D-amino acid sequence FRWLLRQLARLAQLAKLTPVKLTPV (SEQ ID NO: 1).

7. The method of claim 1, wherein the peptide antagonist is a cell-penetrating peptide.

8. The method of claim 1, wherein the peptide antagonist is ST316.

9. The method of claim 8, wherein the peptide antagonist is administered to the subject at a dose of about 0.25-12 mg / kg.

10. The method of claim 1, wherein the immunomodulator is selected from the group consisting of a checkpoint inhibitor, a cytokine, and an immune adjuvant.

11. The method of claim 1 , wherein the immunomodulator is an antibody or an antibody-drug conjugate.

12. The method of claim 11, wherein the antibody or antibody-drug conjugate is selected from the group consisting of amivantamab, belantamab mafodotin-blmf. bevacizumab, cetuximab, denosumab. dinutuximab. enfortumab vedotin-ejfv, margetuximab, naxitamab-gqgk, necitumumab, panitumumab, pertuzumab, ramucirumab, Sacituzumab govitecan-hziy, tebentafusp-tebn, tisotumab vedotin, trastuzumab, trastuzumab deruxtecan, and trastuzumab emtansine.

13. The method of claim 11, wherein the antibody is an anti-PD-1 antibody.

14. The method of claim 10, wherein the checkpoint inhibitor targets at least one of PD-1, PD-L1, CTLA-4, LAG-3, TIGIT, or VISTA.

15. The method of claim 10, wherein the checkpoint inhibitor is selected from the group consisting of atezolizumab, avelumab, cemiplimab. dostarlimab, durvalumab, ipilimumab, nivolumab, pembrolizumab, relatimab. and a combination thereof.

16. The method of claim 10, wherein the cytokine targets at least one of the IL-2 pathway, the IL-2R pathway, the 1FNAR1 pathway, or the 1FNAR2 pathway.

17. The method of claim 10, wherein the cytokine is selected from the group consisting of aldesleukin, granulocyte-macrophage colony-stimulating factor, interferon alfa- 2a, interferon alfa-2b, and peginterferon alfa-2b.

18. The method of claim 10, wherein the immune adjuvant targets the Toll-like receptor 7 pathway or the Toll-like receptor 3 pathway.

19. The method of claim 10, wherein the immune adjuvant is selected from the group consisting of Imiquimod and Poly ICLC.

20. The method of claim 1, wherein the pharmaceutical composition comprising the antagonist of P-catenin and / or the pharmaceutical composition comprising the immunomodulator is administered intravenously.

21. The method of claim 1 , wherein the pharmaceutical composition comprising the antagonist of P-catenin and the pharmaceutical composition comprising the immunomodulator are administered to the subject on different days.

22. The method of claim 1, wherein the pharmaceutical composition comprising the antagonist of P-catenin is administered at least once weekly for at least three weeks.

23. The method of claim 1, wherein the pharmaceutical composition comprising the antagonist of p-catenin is administered once every two weeks for at least four weeks.

24. The method of claim 1. wherein the pharmaceutical composition comprising the immunomodulator is administered at least once weekly for at least three weeks.

25. The method of claim 1. wherein the pharmaceutical composition comprising the immunomodulator is administered once every two weeks for at least four weeks.

26. The method of , wherein the pharmaceutical composition comprising the immunomodulator is administered once every three weeks for at least six weeks.

Citation Information

Patent Citations

  • Methods for treating solid tumors

    US20220265792A1

  • Modified BCL9 Mimetic Peptides

    US20220275036A1

  • Administration of CEBP-beta antagonist and methods of use

    WO2021262604A2

  • Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with KRAS inhibitors

    WO2023009716A1

  • Methods of treating or preventing infusion-related reactions

    WO2023122355A2